Biopharma · FDA Approvals · Stock
VYGR Voyager Therapeutics
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central…
Assets on file: VY1706
Catalyst calendar
Dated catalysts for VYGR, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for VYGR, newest first.
VYGRVoyager TherapeuticsVoyager Therapeutics: FDA clears IND for VY1706 tau-silencing gene therapy
The FDA cleared the IND for VY1706, allowing the company to proceed with a first-in-human, multi-site, open-label, dose-escalation trial in early AD patients with confirmed tau pathology. Dosing is planned to begin in the second half of 2026, with up to 18 participants across three cohorts receiving a single intravenous dose.
Peers by market cap
Companies in the same sector closest to VYGR in market value.
IMUXImmunicMarket cap $106.4M · 1 tracked drug · 3 upcoming catalysts
PDSBPDS BiotechnologyMarket cap $104.4M · 2 tracked drugs · 8 upcoming catalysts
UNCYUnicyciveMarket cap $104.2M · 1 tracked drug
ANIXAnixa BiosciencesMarket cap $108.5M · 3 tracked drugs · 1 upcoming catalyst
ENGNenGeneMarket cap $102.5M · 1 tracked drug · 1 upcoming catalyst
AVXLAnavex Life SciencesMarket cap $110.3M · 1 tracked drug
NERVMinerva NeurosciencesMarket cap $110.8M · 1 tracked drug · 1 upcoming catalyst
ORGOOrganogenesisMarket cap $98.8M · 1 tracked drug